Atypical Cell

Overview Forums Topics Doctor Questions eHealthpedia
Ask our Community
Members
eHealthpedia Articles
Mono Diagnosis
Do you need to see a specialist for mono? What tests can confirm a diagnosis? And what should you expect when you visit the doctor's office? Get prepared here.
Testicular Cancer Causes and Risk Factors
Age, body size and genetics all play roles in who gets testicular cancer. Are you at risk? Learn more about how to avoid testicular cancer risks and its causes.
More
Topics
bia55
bia55 / Thyroid Cancer
Azlisa
Azlisa / Breast Cancer
paranoid1980
paranoid1980 / HIV and AIDS
worriedboy10
worriedboy10 / HIV and AIDS
More
Doctor Answers
Dr. Goce Aleksovski
Dr. Goce Aleksovski / Sexual Health - Women
More
News
Press Release
Alexion Pharmaceuticals Inc. Posted on:23 Sep 11 Soliris, a first-in-class terminal complement inhibitor, specifically targets uncontrolled complement activation, and is indicated for the treatment of patients with aHUS to inhibit complement-mediated TMA.
Alexion Receives CHMP Positive Opinion for Soliris® (eculizumab) in Patients with Atypical Hemolytic Uremic Syndrome ...
CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals today announced that the European CHMP adopted a positive opinion recommending that Soliris® (eculizumab) be extended to include the treatment of patients with aHUS in Europe.
Soliris® (eculizumab) Approved by FDA for All Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the U.S. Food and Drug Administration ...
Dining | MontereyCountyWeekly.com
I learned the ways of canning salsa from a used-car salesman named Roy. He looks like Willie Nelson, bandana and all, and speaks with a southern twang thick enough to get your truck stuck in. ...
Soliris® (Eculizumab) Approved By FDA For All Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
Alexion Pharmaceuticals, Inc. recently announced that the U.S. Food and Drug Administration (FDA) has approved Soliris® (eculizumab) for the treatment of all pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS).